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In a previous study we applied a three-step avidin–biotin pretargeting approach to target
90Y-biotin to the tumour in patients
with recurrent high grade glioma. The encouraging results obtained in this phase I–II study prompted us to apply the same
approach in an adjuvant setting, to evaluate (i) time to relapse and (ii) overall survival. We enrolled 37 high grade glioma
patients, 17 with grade III glioma and 20 with glioblastoma, in a controlled open non-randomized study. All patients received
surgery and radiotherapy and were disease-free by neuroradiological examinations. Nineteen patients (treated) received
adjuvant treatment with radioimmunotherapy. In the treated glioblastoma patients, median disease-free interval was 28 months
(range=9–59); median survival was 33.5 months and one patient is still without evidence of disease. All 12 control
glioblastoma patients died after a median survival from diagnosis of 8 months. In the treated grade III glioma patients median
disease-free interval was 56 months (range=15–60) and survival cannot be calculated as only two, within this group, died.
Three-step radioimmunotherapy promises to have an important role as adjuvant treatment in high grade gliomas, particularly
in glioblastoma where it impedes progression, prolonging time to relapse and overall survival. A further randomized trial is
justiﬁed.
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Despite years of intensive research, the prognosis for high grade
gliomas (grade III glioma and glioblastoma (GBM)) remains
conspicuously poor. Median survival for adults with glioblastoma
is 8–12 months after diagnosis (Walker et al, 1985). The outlook
is somewhat better for grade III glioma with a 38–50% 2-year
survival rate. However, primary high grade brain tumours are
highly resistant to currently available therapies. Occasionally
responses to surgery, radiotherapy or single-multiple chemotherapy
are observed in the setting of recurrent tumours, but these
responses are usually of short duration, resulting in a brief survival
time. Thus, new treatments, such as gene therapy (Culver et al,
1992; Roth and Cristiano, 1997) and the use of monoclonal anti-
bodies (MoAbs) in association with cytotoxic agents are being
investigated (Zalutsky et al, 1989).
Intralesional radioimmunotherapy (RIT) for high grade gliomas
using anti-tenascin monoclonal antibodies labelled with iodine-131
has been used with encouraging results and without major side
effects (Riva et al, 1994). However, the limitations of this approach
are the low penetrance of the beta particles into the tumour and
the impossibility of treating multifocal tumours. Systemic
administration of radiolabelled MoAbs is not generally applicable,
since the quantity of radioactivity that localizes in the solid tumour
after intravenous administration is signiﬁcantly lower than that
needed to obtain therapeutic effects (Larson, 1990).
One major limitation of the technique is the frequently unfa-
vourable tumour-to-non tumour distribution of radiolabel, due
to the pharmacokinetics of the MoAb, and the binding to non-
speciﬁc tissues (Goodwin, 1987; Goodwin et al, 1988). Among
the strategies proposed to overcome these problems, a three-step
method (pretargeting) that temporally separates the principal
targeting reagent from the radiolabel has given encouraging results
(Paganelli et al, 1988; 1991; Magnani et al, 1996). By exploiting
the high afﬁnity of biotin–avidin binding (Wilchek and Bayer,
1984) pretargeting of tumours with biotinylated MoAb and strep-
tavidin has the advantage of decreasing the load of targeting
MoAb, while at the same time increasing the speciﬁc delivery of
radiolabel to the disease site (Hnatowich et al, 1987; Sung and
van Osdol, 1995). In the ﬁrst step, the patient is injected with
a biotinylated MoAb that binds to an antigen on the tumour cell
surface. In pharmacokinetic studies, much of the antibody that
does not bind to tumour clears from circulation within 24–
48 h (Cremonesi et al, 1999) and the optimum tumour to back-
ground ratio is achieved. In the second step we inject streptavidin
which binds to MoAb on the tumour surface and promote the
clearance of the unbound MoAb. This is followed, one to several
hours later, by biotinylated effector molecules, often radionuclides.
In a phase I–II therapeutic study (Paganelli et al, 1999) 48
patients with grade III/IV glioma were treated with anti-tenascin
Ab and yttrium-90 labelled biotin. Two months after treatment,
12 out of 48 patients showed objective reduction in tumour mass
(three complete remissions) and another 52% of the patients had
stable disease. Even 12 months after treatment, 17% of the
patients still showed tumour reduction.
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www.bjcancer.comThese results prompted the present study in which the same
approach was used in the adjuvant setting soon after surgery and
radiotherapy. The end-points were: (i) time to relapse; and (ii)
overall survival.
METHODS
Patients
From December 1994 to August 1997 we enrolled 37 high grade
glioma patients, 17 with grade III glioma (anaplastic astrocytoma
AA; oligodendroglioma OD; oligoastrocytoma OA) and 20 with
GBM; 16 were females and 21 were males, age range was 19–83
years. Inclusion criteria were: (a) tenascin expression in the tumour
demonstrated immunohistochemically; (b) prior computed tomo-
graphy (CT) or magnetic resonance (MR) studies revealing no
evidence of disease; (c) baseline blood and kidney function tests
in normal range; and (d) Karnofsky performance status (KPS)
470%. Exclusion criteria were: (a) KPS 570; (b) presence of
macroscopic disease on CT or MR; (c) the presence of a known
second cancer; (d) history of allergic or anaphylactic reactions;
and (e) pregnancy. The study was approved by the Ethical
Committee of the European Institute of Oncology and all patients
were informed of the nature, aim and potential risks of the study;
treated patients signed a consent form before starting therapy.
The study was designed as an open, controlled, non-randomized
one. All patients received surgery and radiotherapy; a central
pathologyreviewwasperformed.Ninewerealsogivenplatinum-based
chemotherapy, before and during radiotherapy, four in the treatment
group and ﬁve in the control group. Nineteen patients were given the
adjuvant RIT with
90Y-biotin and thus formed the treatment group.
The remaining 18 patients served as controls and received no further
treatment.Patientswereassignedtothecontrolgroupfor:(i)lowavail-
ability of monoclonal antibodies, (ii) insufﬁcient expression of
tenascinbythetumour,or(iii)ahistoryofallergicreactions;otherwise
they would have been assigned to the treatment group and given RIT.
Moreover three control patients speciﬁcally refused RIT, due to other
medical advice (they preferred chemotherapy).
RIT was administered to treatment group patients within a
month of baseline assessment by MR or CT scan after 1 month
from the end of radiotherapy.
Routine blood tests and liver and renal function tests were
performed before and after RIT. Antibodies against murine antibo-
dies, avidin and streptavidin were assayed in serum 30–40 days
after RIT. Check-ups, including clinical examination (evaluation
of performance status, quality of life, number of seizures, drug
intake) and CT or MR scans, were scheduled at 3-month intervals
starting 2 months after the end of RIT.
Control patients were also assigned clinical and radiological
checks every 3 months. However they complied poorly, so it was
not possible to calculate the disease-free interval (DFI) in this
group, and only data on survival are available. Detailed charac-
teristics of both groups are reported in Tables 1 and 2.
Reagents
Anti-tenascin MoAb BC4 was from Sorin Biomedica (Saluggia, Italy).
MoAbs were biotinylated by BIO-SPA (Milan, Italy) as described
(Paganelli et al, 1991). The macrocyclic chelating agent 1,4,7,10-tetra-
azacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA), linked to
biotin via an amino acid side chain modiﬁed by amide N-methyla-
tion, was provided by the NeoRx Corporation (Seattle, WA, USA).
Yttrium-90 chloride in hydrochloric acid (0.04 M) was purchased
from MAP Medical Technologies (Finland).
Radiolabelling and administration protocols
The radiolabelling procedure and pre-targeting protocol were
performed as described previously (Paganelli et al, 1999). Brieﬂy,
each patient was given 35 mg m
72 i.v. of biotinylated MoAb
against tenascin. This was followed 24–36 h later by 30 mg of
avidin as rapid i.v. bolus (chase), followed 30 min later by 50 mg
of streptavidin in 100 ml of saline with 2% human albumin.
Sixteen to 18 h later 2 mg of DOTA-biotin ligand, labelled with
90Y-chloride (2.2 GBq m
72) were injected.
Data analysis and statistical evaluation
The ﬁrst post-treatment evaluation by CT or MR was performed
40–60 days later and repeated every 3–4 months. The disease-free
interval from diagnosis (that we considered to be surgery) until the
ﬁrst sign of progression on neuroimaging was calculated. Patients
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Table 1 Characteristics of patients who underwent RIT treatment
Age DFI Survival Follow-up
No. (years) Sex Histology CT (months) (months) (t)
1 41 F OD grade 3 27 53 PD t
2 45 F OA grade 3 27 28 PD
3 48 M OA grade 3 X 60 69 PD
4 54 M OA grade 3 58 58 DF
5 40 F OD grade 3 51 54 PD
6 31 M AA grade 3 15 25 PD t
7 53 M AA grade 3 51 51 DF
8 49 M AA grade 3 X 34 61 PD
9 36 M AA grade 3 57 57 DF
10 52 M AA grade 3 56 57 PD
11 57 M OD grade 3 50 50 DF
12 55 F GBM 39 43 PD
13 70 M GBM 9 20 PD t
14 39 F GBM 11 14 PD t
15 40 F GBM 34 36 PD
16 47 F GBM 59 59 DF
17 58 M GBM X 22 31 PD t
18 40 F GBM 10 14 PD t
19 36 M GBM X 35 36 PD t
F: female; M: male; t: dead patient; OD: oligodendroglioma; OA: oligoastrocytoma; AA: anaplastic
astrocytoma; GBM: glioblastoma; CT: chemotherapy; DFI: disease free interval; PD: progressive
disease; DF: disease free.
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vations and the DFI was calculated from the date of diagnosis to
the date of latest follow-up. For both treated and control patients
the time from diagnosis till death was recorded. Patients who were
still alive were treated as censored with the date of latest follow-up
used to give the survival time.
The two groups of patients, (17 Grade III and 20 Grade IV),
were analyzed and are shown separately since they have different
prognoses. Kaplan-Meier estimation of survival and a log-rank test
were applied to assess any differences between treated and
untreated patients. A Cox proportional hazard model was ﬁtted
to take into account a possible confounding effect of age (Therneau
and Grambsch, 2000). A permutation test was also done as there is
a small number of patients in the groups (Davison and Hinkley,
1997). A 5% level of signiﬁcance was used with 500 Monte Carlo
simulations. All the analyses were done in S-PLUS 2000 Profes-
sional Release 2 (MathSoft, Inc. 1988–1999 Seattle, USA).
RESULTS
Toxicity
In all patients the treatment was well-tolerated. None developed
renal or liver alterations during follow-up. One patient, who had
previously received monoclonal antibodies and avidin for diag-
nostic purposes, developed a mild allergic reaction during avidin
administration. No patient developed side effects to biotinylated
MoAbs or
90Y biotin injection.
The presence of antibodies against the injected reagents was
assayed before and after treatment. Almost all patients (90%)
developed anti-streptavidin antibodies, 70% developed anti-avidin
antibodies and 20% developed antibodies against the murine
MoAbs. These results are closely similar to those we published
previously; in particular they conﬁrm the low frequency of reaction
to murine MoAbs and the high immunogenicity of streptavidin
(Paganelli et al, 1997).
Fifty-eight per cent of patients did not develop haematological
toxicity; in the remainder (42%) hematological toxicity was grade
I or II. The nadir occurred 3–4 weeks after treatment with full
recovery in all cases in 4–6 weeks. There was no correlation
between toxicity grade and previous exposure to chemotherapy.
These data conﬁrm the safety of administering up to
2.22 GBq m
72 of
90Y-biotin using our protocol (Paganelli et al,
1999).
Therapeutic effect
The two groups of patients are shown separately since they have
different prognoses.
Grade IV glioma patients (GBM) Five of the eight grade IV
treated patients and all of the 12 controls died. The estimates of
median survival in the two groups were, respectively, 33.5 months
(95% CI=(20, NA), range=(14–59)) and 8 months (95% CI=(8,
NA); range=(5–25)). This difference was signiﬁcant, (log-rank
test=12.6 on 1 d.f.), and the corresponding curves are shown in
Figure 1. The P-value from the permutation test was P=0.014.
The estimated median Disease Free Interval, in the eight treated
patients, was 28 months (95% CI=(11, NA), range=(9–59)).
Figure 2 is an example of long lasting response to adjuvant RIT
in a patient who had surgery for glioblastoma, showing a good
response to RIT.
Grade III glioma patients Only two of the 11 grade III treated
patients died, so the estimate of the median overall survival is not
available. Among the controls, such an estimate was 33 months
(95% CI=(19, NA), range=(9–50)). The difference in survival
was signiﬁcant (log-rank test=6.1 on 1 d.f.) and the K-M estimated
curves are shown in Figure 1. The P-value from the permutation
test was P=0.002. The estimated median Disease Free Interval, in
the 11 treated patients, was 56 months (95% CI=(34, NA),
range=(15–60)).
DISCUSSION
Despite their local pattern of growth and progression, malignant
gliomas are the third most important cause of cancer death in
the 15–34 age range (Walker et al, 1985; Mahaley et al, 1989; Salc-
man, 1990) with median survival times of 6–12 months for GBM
and 15–27 months for grade III glioma (Florell et al, 1992).
Current recommended treatment for high grade gliomas is
surgical resection followed by radiation therapy (RT) (Leibel and
Sheline, 1987). However even with complete macroscopic debul-
king and external RT at doses above 60 Gy (Salazar et al, 1979),
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Table 2 Characteristics of control patients (did not undergo RIT treatment)
Age Survival Follow-up
No. (years) Sex Histology CT (months) (t)
1 27 M AA grade 3 34 PD t
2 32 M AA grade 3 32 PD t
3 53 F OD grade 3 X 9 PD t
4 46 M OD grade 3 X 19 PD t
5 33 F AA grade 3 50 PD
6 19 F AA grade 3 48 DF
7 32 F GBM X 8 PD t
8 70 M GBM X 8 PD t
9 72 M GBM 11 PD t
10 46 M GBM 12 PD t
11 44 M GBM X 15 PD t
12 83 F GBM 5 PD t
13 57 F GBM 8 PD t
14 71 F GBM 8 PD t
15 61 M GBM 6 PD t
16 65 M GBM 14 PD t
17 50 M GBM 13 PD t
18 42 F GBM 25 PD t
F: female; M: male; t: dead patient; OD: oligodendroglioma; AA: anaplastic astrocytoma; GBM: glioblas-
toma; CT: chemotherapy; PD: progressive disease; DF: disease free.
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ã 2002 The Cancer Research Campaign British Journal of Cancer (2002) 86(2), 207–212the tumour inevitably recurs, probably due to the presence of
malignant cells at the edge of surgical cavity which are not killed
by irradiation (Burger, 1983). Despite the use of aggressive
combined therapies, the poor prognosis for these patients reﬂects
lack of sufﬁciently potent agents with adequate tumour speciﬁcity.
In the present study, our main objectives were the evaluation of
the disease free interval and the overall survival, following RIT in
combination with surgery, radiotherapy and chemotherapy. The
fact that our patient population was a selected one (either active
or control; the macroscopically disease free status; good clinical
conditions) enhances the overall clarity of the present study
because it simpliﬁes the interpretation of the data and facilitates
the comparison with trials involving different therapeutical
approaches. The absence of macroscopic disease after surgery, a
good KPS are, of course, favourable prognostic factors; although
they do not exclude from recurrence and patients remain with a
short life expectancy in both groups.
The three-step method we have developed, which exploits the
avid and speciﬁc binding of the avidin/biotin system, targets radio-
nuclides to speciﬁc MoAbs already previously localized on the
tumour cells (Wilchek and Bayer, 1984). Pre-clinical (Hnatowich
et al, 1987; Paganelli et al, 1990) and clinical (Kalofonos et al,
1990; Paganelli et al, 1994) studies have shown that multi-step
avidin/biotin methods result in improved localization of radionu-
clides to tumours compared to radiolabelled MoAbs (Sung and
van Osdol, 1995; Beaumier et al, 1995). Furthermore encouraging
results were obtained in a phase I-II clinical study (Paganelli et
al, 1999).
The results of this pilot study are promising, even though they
relate to a small patient population. Four of 11 grade III glioma
patients were disease free at latest follow-up and eight patients have
been followed for more than 30 months without progression. More
remarkable were the outcomes in the treated GBM patients, in
whom DFI and consequently life expectancy was much improved
relative to our controls. The group has a DFI of 28 months and
overall survival of 33.5 months from diagnosis with one of the
original eight patients disease free and in follow-up at latest
follow-up. Survival times in both the treated grade III (log rank
test=6.1, P=0.013) and treated GBM patients (log rank test=12.6,
P50.001) were signiﬁcantly longer than in the corresponding
controls. The ﬁtted models accounted for a potential effect of
age and no difference was found, overall, in the two groups.
Although the controls for Grade IV were slightly older and the
controls for Grade III were slightly younger than their respective
treated patients, such a difference was not statistically signiﬁcant.
A treatment effect is, in fact, still evident after adjusting for age.
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Figure 1 Survival curves comparing treated and control patients. Left: grade III glioma; right grade IV glioma.
August '96 January '97 May '98 September '99
Figure 2 MR study of a female patient (47 years old; No. 16) who had surgery for glioblastoma in April 1996: set of images starting from the baseline
evaluation to the last control (September 1999): no evidence of relapse. The patient is scheduled for a new MR in summer 2001.
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greater group, they would constitute highly convincing evidence
that our 3-step RIT protocol is effective in improving survival
and DFI in these almost invariably fatal malignancies. Therefore
our results are only suggestive of an improvement in survival.
Nevertheless we believe that this non-randomized study provides
useful information, particularly in the context of a very poor prog-
nosis disease such as GBM, in which non-randomized studies are
of use, as GBM is a rare advanced and severe cancer (Altman
and Bland, 1999). In particular the results in our glioblastoma
patients strongly suggest RIT should be more widely used as adju-
vant therapy in this condition.
The low toxicity of high dose
90Y-biotin with three-step pre-
targeting strategy is an important advantage over the use of directly
labelled antibodies (Paganelli et al, 1988). Using this approach the
radiolabelled material is cleared quickly from the blood-pool, has
favourable biodistribution and is rapidly excreted via the kidneys.
This entails acceptable absorbed doses to normal organs
(kidneys: 1.6+1.1; liver: 0.3+0.2 mGy MBq
71) including red
marrow (0.10+0.05 mGy MBq
71) (Cremonesi et al, 1999).
Furthermore, one of the main therapeutic advantages of radionu-
clides, compared to other cytotoxic agents, is their potential for
overcoming the problem of tumour heterogeneity: high grade glio-
ma contains not only viable areas but also hypoxic and necrotic
cells. Therefore a radionuclide with high energy emission, such as
90Y( E bMAX= 2.2 MeV) that penetrate up to 11 millimetres of
tissue can kill tumour cells that have no MoAbs on their surface
(crossﬁre effect).
A number of points arise from the results of this trial. Firstly,
RIT is conﬁrmed as highly active against malignant glioma, yet
does not cause major adverse events, as previously described (Paga-
nelli et al, 1999). Secondly the effect RIT on GBM is interesting: it
considerably prolonged DFI and overall survival relative to the
untreated group. We also believe that there is room to further
improve the efﬁcacy of the method by modifying its timing. It
may be advantageous to administer RIT immediately after debul-
king surgery, in order to exploit the greater permeability of the
blood–brain barrier at that time. This would be expected to
expose more malignant cells to the radionuclide and hence limit
the local spread of the cancer.
We emphasize however that RIT should be used as part of a
combined modality approach. To illustrate this we note the results
of a combined treatment in a patient with advanced oropharyngeal
carcinoma treated with surgery, radio-chemotherapy and three-step
radioimmunotherapy (Paganelli et al, 1998). In this patient a
partial tumour response was achieved after surgery and radio-
chemotherapy. After administration of RIT the patient presented
a complete response that lasted more than 17 months.
The combined modality approach to treating brain tumours was
introduced about 30 years ago; it remains the most effective
approach we have. The promise is that the combination of surgery,
radiotherapy, chemotherapy and RIT may provide, at last, a way of
increasing life expectancy in high grade glioma patients (O’Reilly et
al, 1993).
In conclusion, three-step RIT could have an important role as
adjuvant treatment in high grade gliomas, as it interferes with
progression, prolonging time to relapse and overall survival.
Presumably, based on these results, this technique should be
performed in an adjuvant setting in a larger number of patients
with high grade glioma and a randomized trial is fully justiﬁed.
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